Custom COVID-19 (SARS-CoV-2) Services
ProSci continues all operations and is active in efforts to develop diagnostics and therapeutics against the COVID-19 virus SARS-CoV-2. During the 2003 SARS outbreak, ProSci developed numerous antibodies to the SARS coronavirus as well as other viral infectious disease pathogens. In response to the novel coronavirus COVID-19 pandemic, we support COVID-19 research through our custom antibody services and products . ProSci has extensive expertise in developing and expressing polyclonal, monoclonal and recombinant single domain antibodies.
To review our existing COVID-19 (SARS-CoV-2) antibodies and recombinant proteins visit our catalog.
Contact us to collaborate or assist with custom antibody development projects including:
- COVID-19 (SARS-CoV-2) ELISA Pairs Antibody Development for Diagnostic Assays & Detection Screening Kits
- COVID-19 (SARS-CoV-2) Broadly Neutralizing Antibody Development for Vaccine Research & Development
- COVID-19 (SARS-CoV-2) Novel Recombinant Single Domain Antibody Development
- COVID-19 (SARS-CoV-2) Peptide Synthesis & Serum Purification for Commercial & Research Purposes
ProSci COVID-19 Antibody Expertise
- 20+ years Infectious Disease and Vaccine Research
- 18+ years Coronavirus Antibody Product Development
- Novel Recombinant Single Domain Antibody Development Platform
- Comprehensive Antibody Services and success
- Your scientific partner providing guided antibody success
Infectious Disease Research
For over 20 years, ProSci Inc has been at the forefront of research and development for high quality antibodies during infectious disease outbreaks. In 2007, we were the first to develop high quality commercial antibodies for H5N1 AVIAN Influenza [Product Poster] [Antibody Research Poster], seasonal H1N1 and other viral respiratory diseases. In addition we have assisted others in antibody development towards Ebola, Zika, MERS, Malaria and other infectious disease research.
HIV Vaccine Research
ProSci led a multi-year R&D project to develop broadly neutralizing antibodies by targeting the viral glycan shield for an HIV vaccine. This study resulted in one patent, six peer reviewed publications, and multiple SBIR awards from NIH. This 15+ year study built a profound foundation for successfully developing various custom antibodies for infectious disease. In addition, a commercial Sandwich ELISA was developed which detects HIV in serum early.
Coronavirus Antibody Product Development
Since 2003, ProSci Inc has researched coronavirus SARS-CoV resulting in the development of high quality commercial antibodies for SARS-CoV spike, envelope, and matrix proteins. Comparing SARS-Cov to the current novel coronavirus SARS-CoV-2, there is approximately 79% sequence identity to SARS-CoV, thus with ProSci Inc's comprehensive knowledge and expertise in regards to SARS-CoV and antibody development, we can help accelerate your research through the following:
- Commercial Antibody Research & Development
- SARS-CoV-2, SARS-CoV, & Other Covonavirus Antibody Cocktails
- Antibody Application Project Design Assistance
Infectious Disease Custom Projects
With over 20,000 custom antibodies made, ProSci Inc has worked with a variety of customers in both commercial and academic settings for infectious diseases such as Ebola, Zika, MERS, and Influenza. We have helped developed antibodies for diagnostic assays, antibodies for vaccine research, and antibodies for novel difficult targets. The comprehensive breadth and depth of our antibody expertise towards infectious disease enhances antibody development success that is specific and sensitive to your antibody needs.
Our mission is to provide extensive expertise in developing valuable antibodies to support our partners in order to improve human health globally, thus making ProSci your preferred partner for custom COVID-19 antibody development. Our many years of antibody research in infectious disease, service offerings, and investment in your success provides antibody success as if we were an extension of your lab.
Contact us today for your COVID-19 antibody development needs.